CellaVision combines a dominant automated morphology moat, recovering demand, and BMA-driven upside into an attractive but execution-sensitive five-year asymmetric return opportunity.
Overview
CellaVision is a specialized medical-technology leader that automates blood and body-fluid morphology through digital scanners, AI pre-classification software, and recurring reagents. Its systems can reduce hands-on slide-review time by up to 70%, and its more than 60% market share, over 9,500-system installed base, proprietary clinical image data, regulatory track record, and deep OEM partnerships create a durable competitive position. Q2 2026 showed recovery from Q1 distributor destocking: sales rose 4.5% year over year to SEK 200 million, or 5.6% organically excluding -1.1% FX, while the Americas reached a record SEK 105 million. Reported EBITDA margin was 27%, rising to 32% excluding SEK 9 million of CEO-transition costs. **The principal catalyst is Bone Marrow Aspirate software**, which has generated initial EMEA revenue and is expected to add 1.0%–2.0% to 2026 sales growth if U.S. FDA 510(k) clearance arrives before year-end. At SEK 147.20, valuation of 24.3x–26.7x trailing P/E and 4.5x LTM sales is demanding but supported by an asset-light, self-funding model; the five-year probability-weighted target is SEK 237.99.